Approval · Notice of Compliance 13368 · 2012
SIMVASTATIN: Notice of Compliance 13368
Issued June 8, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13368
- Date
- June 8, 2012
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Lipid Metabolism Regulator
- Canadian reference product
- ZOCOR (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SIMVASTATIN | 02386291 | Marketed |
| SIMVASTATIN | 02386305 | Marketed |
| SIMVASTATIN | 02386313 | Marketed |
| SIMVASTATIN | 02386321 | Marketed |
| SIMVASTATIN | 02386348 | Marketed |
Medicinal ingredients
- SIMVASTATIN 5 MG per TAB
- SIMVASTATIN 10 MG per TAB
- SIMVASTATIN 20 MG per TAB
- SIMVASTATIN 40 MG per TAB
- SIMVASTATIN 80 MG per TAB